Suppr超能文献

[原发性乳腺癌中尿激酶型纤溶酶原激活物免疫组化测定的预后价值]

[Prognostic value of immunohistochemical determination of urokinase plasminogen activator in primary breast cancers].

作者信息

Göhring U J, Scharl A, Thelen U, Ahr A, Titius B R

机构信息

Klinik und Poliklinik für Frauenheilkunde und Geburshilfe, Universität zu Köln.

出版信息

Pathologe. 1995 Nov;16(6):398-403. doi: 10.1007/s002920050120.

Abstract

There is ample evidence that the protease urokinase plasminogen activator (uPA) plays a role in invasion and spread of tumours. Several publications suggest its biochemical measurement in tumour cytosols to be of prognostic significance in breast carcinomas. Our study set out to determine whether the immunohistochemical detection of uPA in formalin-fixed, paraffin-embedded primary breast cancer tissues is of prognostic relevance. We tested 269 surgical specimens of primary ductal infiltrating carcinoma immunohistochemically using a modified avidin-biotin method. Some 57% of carcinoma specimens yielded specific positive staining in tumour cells. Detection of uPA correlated to tumour grade (P = 0.04), and to the detected level of the proliferation marker PCNA (P = 0.002), but not to patients' age or menopausal status, tumour size, nodal or steroid receptor status (P > 0.05). At median 68 months' follow-up, 34% of patients had experienced tumour relapse and 28% had died from cancer. Clinical course was correlated significantly to tumour size, tumour grade, nodal and steroid hormone receptor status (P < 0.05). Immunohistochemical detection of uPA, however, could not be demonstrated to be of any prognostic significance with regard to relapse-free or overall survival (P > 0.05) in the total study group or in the N0 (n = 120) and N + (n = 144) subgroups, regardless of whether univariate or multivariate analysis was applied.

摘要

有充分证据表明,蛋白酶尿激酶型纤溶酶原激活剂(uPA)在肿瘤的侵袭和扩散中起作用。一些出版物表明,在肿瘤细胞溶胶中对其进行生化检测对乳腺癌具有预后意义。我们的研究旨在确定在福尔马林固定、石蜡包埋的原发性乳腺癌组织中进行uPA的免疫组化检测是否具有预后相关性。我们使用改良的抗生物素蛋白-生物素方法对269例原发性导管浸润癌手术标本进行了免疫组化检测。约57%的癌标本在肿瘤细胞中产生特异性阳性染色。uPA的检测与肿瘤分级(P = 0.04)以及增殖标志物PCNA的检测水平相关(P = 0.002),但与患者年龄、绝经状态、肿瘤大小、淋巴结或类固醇受体状态无关(P > 0.05)。在中位随访68个月时,34%的患者出现肿瘤复发,28%的患者死于癌症。临床病程与肿瘤大小、肿瘤分级、淋巴结和类固醇激素受体状态显著相关(P < 0.05)。然而,在整个研究组或N0(n = 120)和N +(n = 144)亚组中,无论采用单因素分析还是多因素分析,uPA的免疫组化检测在无复发生存或总生存方面均未显示出任何预后意义(P > 0.05)。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验